Your browser doesn't support javascript.
loading
Expamers: a new technology to control T cell activation.
Poltorak, Mateusz P; Graef, Patricia; Tschulik, Claudia; Wagner, Michaela; Cletiu, Vlad; Dreher, Stefan; Borjan, Bojana; Fraessle, Simon P; Effenberger, Manuel; Turk, Martin; Busch, Dirk H; Plitzko, Juergen; Kugler, David G; Ragan, Seamus; Schmidt, Thomas; Stemberger, Christian; Germeroth, Lothar.
Afiliação
  • Poltorak MP; Juno Therapeutics GmbH, a Bristol-Myers Squibb Company, Grillparzerstr. 10, 81675, Munich, Germany. mateusz.poltorak@bms.com.
  • Graef P; Juno Therapeutics GmbH, a Bristol-Myers Squibb Company, Grillparzerstr. 10, 81675, Munich, Germany.
  • Tschulik C; Juno Therapeutics GmbH, a Bristol-Myers Squibb Company, Grillparzerstr. 10, 81675, Munich, Germany.
  • Wagner M; Juno Therapeutics GmbH, a Bristol-Myers Squibb Company, Grillparzerstr. 10, 81675, Munich, Germany.
  • Cletiu V; Juno Therapeutics GmbH, a Bristol-Myers Squibb Company, Grillparzerstr. 10, 81675, Munich, Germany.
  • Dreher S; Juno Therapeutics GmbH, a Bristol-Myers Squibb Company, Grillparzerstr. 10, 81675, Munich, Germany.
  • Borjan B; Juno Therapeutics GmbH, a Bristol-Myers Squibb Company, Grillparzerstr. 10, 81675, Munich, Germany.
  • Fraessle SP; Juno Therapeutics GmbH, a Bristol-Myers Squibb Company, Grillparzerstr. 10, 81675, Munich, Germany.
  • Effenberger M; Institute for Medical Microbiology Immunology and Hygiene, Technical University of Munich, Munich, Germany.
  • Turk M; Juno Therapeutics GmbH, a Bristol-Myers Squibb Company, Grillparzerstr. 10, 81675, Munich, Germany.
  • Busch DH; Institute for Medical Microbiology Immunology and Hygiene, Technical University of Munich, Munich, Germany.
  • Plitzko J; Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.
  • Kugler DG; Institute for Medical Microbiology Immunology and Hygiene, Technical University of Munich, Munich, Germany.
  • Ragan S; Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany.
  • Schmidt T; Juno Therapeutics Inc., a Bristol-Myers Squibb Company, 400 Dexter Avenue North, Suite 1200, Seattle, WA, 98109, USA.
  • Stemberger C; Juno Therapeutics Inc., a Bristol-Myers Squibb Company, 400 Dexter Avenue North, Suite 1200, Seattle, WA, 98109, USA.
  • Germeroth L; Juno Therapeutics GmbH, a Bristol-Myers Squibb Company, Grillparzerstr. 10, 81675, Munich, Germany.
Sci Rep ; 10(1): 17832, 2020 10 20.
Article em En | MEDLINE | ID: mdl-33082362
T cell activation is a cornerstone in manufacturing of T cell-based therapies, and precise control over T cell activation is important in the development of the next generation T-cell based therapeutics. This need cannot be fulfilled by currently available methods for T cell stimulation, in particular not in a time dependent manner. Here, we describe a modular activation reagent called Expamers, which addresses these limitations. Expamers are versatile stimuli that are intended for research and clinical use. They are readily soluble and can be rapidly bound and removed from the cell surface, allowing nearly instantaneous initiation and termination of activation signal, respectively. Hence, Expamers enable precise regulation of T cell stimulation duration and provide promise of control over T cell profiles in future products. Expamers can be easily adopted to different T cell production formats and have the potential to increase efficacy of T cell immunotherapeutics.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativação Linfocitária / Linfócitos T / Indicadores e Reagentes Limite: Animals / Humans Idioma: En Revista: Sci Rep Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativação Linfocitária / Linfócitos T / Indicadores e Reagentes Limite: Animals / Humans Idioma: En Revista: Sci Rep Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha